S&P 500   4,533.25 (-0.36%)
DOW   35,605.91 (+0.01%)
QQQ   373.50 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.41 (-0.76%)
FB   322.69 (-5.61%)
GOOGL   2,743.34 (-3.33%)
TSLA   902.22 (+0.92%)
AMZN   3,348.00 (-2.53%)
NVDA   226.67 (-0.11%)
BABA   176.90 (-0.29%)
NIO   39.01 (-2.40%)
CGC   13.39 (-4.63%)
GE   103.93 (+0.76%)
AMD   119.51 (+0.15%)
MU   67.50 (-1.66%)
T   25.58 (-0.70%)
F   16.38 (-1.03%)
ACB   7.12 (-3.39%)
DIS   169.06 (-1.33%)
PFE   42.80 (-0.14%)
BA   213.38 (-0.45%)
AMC   36.44 (-7.14%)
S&P 500   4,533.25 (-0.36%)
DOW   35,605.91 (+0.01%)
QQQ   373.50 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.41 (-0.76%)
FB   322.69 (-5.61%)
GOOGL   2,743.34 (-3.33%)
TSLA   902.22 (+0.92%)
AMZN   3,348.00 (-2.53%)
NVDA   226.67 (-0.11%)
BABA   176.90 (-0.29%)
NIO   39.01 (-2.40%)
CGC   13.39 (-4.63%)
GE   103.93 (+0.76%)
AMD   119.51 (+0.15%)
MU   67.50 (-1.66%)
T   25.58 (-0.70%)
F   16.38 (-1.03%)
ACB   7.12 (-3.39%)
DIS   169.06 (-1.33%)
PFE   42.80 (-0.14%)
BA   213.38 (-0.45%)
AMC   36.44 (-7.14%)
S&P 500   4,533.25 (-0.36%)
DOW   35,605.91 (+0.01%)
QQQ   373.50 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.41 (-0.76%)
FB   322.69 (-5.61%)
GOOGL   2,743.34 (-3.33%)
TSLA   902.22 (+0.92%)
AMZN   3,348.00 (-2.53%)
NVDA   226.67 (-0.11%)
BABA   176.90 (-0.29%)
NIO   39.01 (-2.40%)
CGC   13.39 (-4.63%)
GE   103.93 (+0.76%)
AMD   119.51 (+0.15%)
MU   67.50 (-1.66%)
T   25.58 (-0.70%)
F   16.38 (-1.03%)
ACB   7.12 (-3.39%)
DIS   169.06 (-1.33%)
PFE   42.80 (-0.14%)
BA   213.38 (-0.45%)
AMC   36.44 (-7.14%)
S&P 500   4,533.25 (-0.36%)
DOW   35,605.91 (+0.01%)
QQQ   373.50 (-1.00%)
AAPL   149.04 (-0.29%)
MSFT   308.41 (-0.76%)
FB   322.69 (-5.61%)
GOOGL   2,743.34 (-3.33%)
TSLA   902.22 (+0.92%)
AMZN   3,348.00 (-2.53%)
NVDA   226.67 (-0.11%)
BABA   176.90 (-0.29%)
NIO   39.01 (-2.40%)
CGC   13.39 (-4.63%)
GE   103.93 (+0.76%)
AMD   119.51 (+0.15%)
MU   67.50 (-1.66%)
T   25.58 (-0.70%)
F   16.38 (-1.03%)
ACB   7.12 (-3.39%)
DIS   169.06 (-1.33%)
PFE   42.80 (-0.14%)
BA   213.38 (-0.45%)
AMC   36.44 (-7.14%)
NYSEARCA:FBT

First Trust NYSE Arca Biotechnology Index Fund Stock Forecast, Price & News

$163.82
-0.69 (-0.42 %)
(As of 10/22/2021 11:11 AM ET)
Add
Today's Range
$163.38
$163.82
50-Day Range
$161.84
$176.04
52-Week Range
$150.33
$186.51
Volume101 shs
Average Volume59,070 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend Yield0.00%
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive FBT News and Ratings via Email

Sign-up to receive the latest news and ratings for First Trust NYSE Arca Biotechnology Index Fund and its competitors with MarketBeat's FREE daily newsletter.

Basic Details

Issuer First Trust
Fund NameFirst Trust NYSE Arca Biotechnology Index Fund
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:FBT
Inception Date6/19/2006
Fund ManagerDaniel J. Lindquist, Jon C. Erickson, David G. McGarel, Roger F. Testin, Stan Ueland, Chris A. Peterson
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkNYSE Arca Biotechnology Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$1.79 billion
Average Daily Volume$45,178.50
Discount/Premium-0.06%

ETF Expenses

Management Fee0.40%
Other Expenses0.16%
Total Expenses0.56%
Fee Waiver0.00%
Net Expenses0.56%

Administrator, Advisor and Custodian

AdministratorThe Bank of New York Mellon Corporation
AdvisorFirst Trust Advisors L.P.
CustodianThe Bank of New York Mellon Corporation
DistributorFirst Trust Portfolios L.P.
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerRBC Capital Markets

Geographic Exposure of FBT

Currency Exposure of FBT

Sector Exposure of FBT

Industry Exposure of FBT













First Trust NYSE Arca Biotechnology Index Fund (NYSEARCA:FBT) Frequently Asked Questions

What stocks does MarketBeat like better than First Trust NYSE Arca Biotechnology Index Fund?

Wall Street analysts have given First Trust NYSE Arca Biotechnology Index Fund a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but First Trust NYSE Arca Biotechnology Index Fund wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How has First Trust NYSE Arca Biotechnology Index Fund's stock been impacted by COVID-19?

First Trust NYSE Arca Biotechnology Index Fund's stock was trading at $131.15 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FBT stock has increased by 24.9% and is now trading at $163.82.
View which stocks have been most impacted by COVID-19
.

What other stocks do shareholders of First Trust NYSE Arca Biotechnology Index Fund own?

Based on aggregate information from My MarketBeat watchlists, some companies that other First Trust NYSE Arca Biotechnology Index Fund investors own include Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), The Walt Disney (DIS), Annaly Capital Management (NLY), ONEOK (OKE), Valero Energy (VLO), AbbVie (ABBV), Broadcom (AVGO) and Bristol-Myers Squibb (BMY).

What is First Trust NYSE Arca Biotechnology Index Fund's stock symbol?

First Trust NYSE Arca Biotechnology Index Fund trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "FBT."

Who are First Trust NYSE Arca Biotechnology Index Fund's major shareholders?

First Trust NYSE Arca Biotechnology Index Fund's stock is owned by a number of institutional and retail investors. Top institutional investors include McGuire Investment Group LLC (0.29%), Private Advisor Group LLC (0.26%), Kestra Advisory Services LLC (0.21%), Crumly & Associates Inc. (0.17%), Spectrum Wealth Advisory Group LLC (0.14%) and Kestra Private Wealth Services LLC (0.14%).

Which major investors are selling First Trust NYSE Arca Biotechnology Index Fund stock?

FBT stock was sold by a variety of institutional investors in the last quarter, including Kestra Advisory Services LLC, Avantax Advisory Services Inc., Private Advisor Group LLC, IFP Advisors Inc, Crumly & Associates Inc., NEXT Financial Group Inc, Cambridge Advisors Inc., and Great Valley Advisor Group Inc..

Which major investors are buying First Trust NYSE Arca Biotechnology Index Fund stock?

FBT stock was acquired by a variety of institutional investors in the last quarter, including HBW Advisory Services LLC, Koshinski Asset Management Inc., Juncture Wealth Strategies LLC, TPG Financial Advisors LLC, RFG Advisory LLC, McGuire Investment Group LLC, Total Clarity Wealth Management Inc., and Guidance Point Advisors LLC.

How do I buy shares of First Trust NYSE Arca Biotechnology Index Fund?

Shares of FBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is First Trust NYSE Arca Biotechnology Index Fund's stock price today?

One share of FBT stock can currently be purchased for approximately $163.82.

How much money does First Trust NYSE Arca Biotechnology Index Fund make?

First Trust NYSE Arca Biotechnology Index Fund has a market capitalization of $1.79 billion.


This page was last updated on 10/22/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.